Next Generation Diabetes Therapy and Drug Delivery Technologies

1.1 Research Scope: Cutting-edge Tech Convergence

1.2 Research Scope: Next Generation Technologies

1.3 Research Methodology: The Approach Core Value

1.4 Key Findings: Urgent Need to Address a Critical Global Concern

1.5 Key Findings: Different New Approaches Converging to Diabetes Care

1.6 Key Findings: Multidisciplinary Interaction as the Key Instrument

2.1 Industry Value Chain: Key Enabling Technologies Driving Innovation Business Model

2.2 Diabetes Drug Delivery Market Impact: CAGR of 12.7% from 2020 to 2025

2.3 Diabetes Drug Delivery Market Impact: Emerging Markets Gaining Attention for the Next Decade

2.4 Diabetes Drug Delivery Regional Revenue Growth: The Perfect Niche for Each Region for Global Success

2.5 Diabetes Drug Delivery Business Facts: Translation Medicine as Mandatory

3.1 Diabetes Drug Delivery Innovation Fields: The Scenario for Big Technology Synergy

3.2 Diabetes Drug Delivery Innovation in Pharma/Biotech: Novel Therapeutics in the Field

3.3 Diabetes Drug Delivery Innovation in Medtech: Complementing Devices for More Efficient Therapy

3.4 Diabetes Drug Delivery Innovation in Synertech: Leveraging Technology Advances for Smart Therapy

3.5 Diabetes Drug Delivery Innovation Model: The Right Pathway in the Precision Medicine Era

3.6 Diabetes Drug Delivery Innovation Model: New Innovation Strategies and Cooperation Frameworks

3.7 Diabetes Drug Delivery Development Pipeline: Time to Market Averages for Each Approach

3.8 Diabetes Drug Delivery Development Pipeline: Cascade Effect on the Healthcare Systems Efficiency

4.1 Pharma/Biotech: Insulin Human Inhalation Powder

4.2 Pharma/Biotech: TANZEUM (albiglutide)

4.3 Pharma/Biotech: XIGDUO XR

4.4 Pharma/Biotech: Xultophy (IDegLira)

4.5 Pharma/Biotech: Smart Insulin

4.6 Pharma/Biotech: Bile Acid Microcapsules

4.7 Medtech: FreeStyle Libre Flash Glucose Monitoring

4.8 Medtech: Smart Contact Lenses for Glucose Monitoring

4.9 Medtech: Microneedle Pill with Hollow Needles

4.10 Medtech: Autoantibody Measuring Microchip

4.11 Medtech: SmartGuard GlucoSitter

4.12 Medtech: iLet Bihormonal Bionic Pancreas

4.13 Medtech: ITCA 650

4.14 Medtech: G-Pen Mini™ Glucagon Injection

4.15 Synertech: Glucose Nanosensors

4.16 Synertech: Cell Reprogramming via Nanotechnology

4.17 Synertech: 3D Bioplotted Hydrogel Scaffolds

4.18 Synertech: Spherical Nucleic Acids

4.19 Synertech: Engineering ß-Cell Replacement Therapy

4.20 Synertech: Glucose-responsive Insulin-producing Cells

4.21 Other Innovative Technologies to Watch: Combining Smart Devices with Therapeutics

4.22 Other Innovative Technologies to Watch: Novel Cell-based Platforms Targeting Diabetes Care

4.23 Diabetes eHealth Applications to Follow: Internet of Therapy Approach

5.1 Multi-criteria Approach for Benchmarking: Introducing Analytical Hierarchy Process Approach

5.2 Multi-criteria Approach for Benchmarking: Selected Criteria for Assessment

5.3 Multi-criteria Approach for Benchmarking: Level 0 Criteria

5.4 Multi-criteria Approach for Benchmarking: Level 1 Criteria – Research and Development

5.5 Multi-criteria Approach for Benchmarking: Level 1 Criteria – Financial Support and Funding

5.6 Multi-criteria Approach for Benchmarking: Level 1 Criteria – Market Landscape

5.7 Multi-criteria Approach for Benchmarking: Level 2 Criteria

5.8 Multi-criteria Approach for Benchmarking: Graphical Final Results

5.9 Multi-criteria Approach for Benchmarking: Final Analysis

5.10 R&D Benchmarking: Framework for Innovations Assessment

5.11 R&D Benchmarking: Competitive Differentiation as the Basic Rule

5.12 R&D Benchmarking: Time to Market Leading Focus of Main Innovations

5.13 R&D Benchmarking: Several Innovations Addressing Multiple Business Goals

5.14 R&D Benchmarking: The Crucial Need to Support Research and Development

5.15 Final Remarks: High Pressure over Diabetes Care

6.1 Intellectual Property: Over 280,000 Patents Covered during the Past Three Decades

6.2 Intellectual Property: Sustained Interest in Diabetes Care Publishing Trends

6.3 Intellectual Property: Leading Pharmaceutical and Medical Devices Companies at the Front

6.4 Intellectual Property: Distribution by Region and Patent Offices Worldwide

7.1 Key Industry Influencers

7.1 Key Industry Influencers (continued)

7.1 Key Industry Influencers (continued)

7.2 Key Academic Influencers

7.2 Key Academic Influencers (continued)

7.3 Intellectual Property Sources

7.4 Key Granted Patents

7.4 Key Granted Patents (continued)

7.4 Key Granted Patents (continued)

7.4 Key Granted Patents (continued)

7.4 Key Granted Patents (continued)

7.4 Key Granted Patents (continued)

7.4 Key Granted Patents (continued)

Legal Disclaimer

8.1 The Frost & Sullivan Story

8.2 Value Proposition: Future of Your Company & Career

8.3 Global Perspective

8.4 Industry Convergence

8.5 360º Research Perspective

8.6 Implementation Excellence

8.7 Our Blue Ocean Strategy